Choosing between Axsome Therapeutics (AXSM -0.79%) and Moderna (MRNA +4.81%) requires weighing a focused neuroscience portfolio against a broad, potentially revolutionary technology platform that is currently navigating a period of transition.
AXSM & MRNA: Performance Comparison
Axsome focuses on developing therapies for central nervous system disorders, with several products already on the market. Moderna uses its messenger RNA technology to develop vaccines and treatments, attempting to replicate its success in infectious diseases across new areas like oncology and rare diseases.
The case for Axsome Therapeutics
Axsome operates in the competitive world of biotech stocks, focusing specifically on central nervous system (CNS) conditions. The company currently commercializes Auvelity for major depressive disorder and Sunosi for narcolepsy within the United States. Its growth strategy is bolstered by the 2025 FDA approval of Symbravo for migraine treatment, alongside licensing deals with companies like Pharmanovia to expand its reach into Europe and the Middle East.
In FY 2025, revenue reached about $638.5 million, representing a robust growth rate of approximately 66% compared to the previous year. This surge was primarily driven by the continued adoption of its flagship CNS therapies. Despite the impressive top-line performance, the company reported a net loss of about $183.2 million for the year, though this was a significant improvement from the much larger losses recorded in 2024.
As of its December 2025 balance sheet, the company maintained a current ratio of roughly 1.6x. This measures a company’s ability to cover its short-term debts with its short-term assets, suggesting a stable immediate liquidity position. Its debt-to-equity ratio sits at nearly 2.7x, meaning it carries $2.70 in debt for every dollar of equity. Free cash flow for the year was negative $93.9 million, which represents the cash remaining after paying for operations and capital expenditures.
The case for Moderna
Moderna is reinventing its business as pandemic-related demand shifts, leaning on its three approved commercial products. These include its well-known COVID-19 vaccines and mResvia, a vaccine for respiratory syncytial virus (RSV). The company is also heavily invested in its pipeline, most notably through a strategic collaboration with Merck & Co Inc. (MRK +0.60%) to develop a personalized oncology candidate that could transform cancer treatment.
In FY 2025, revenue reached about $1.9 billion, which was a decrease of roughly 39% from the prior year. This decline reflects the anticipated cooling of the global vaccine market as it moves toward a seasonal model. The company reported a net loss of approximately $2.8 billion for the year, reflecting the heavy research and development costs required to advance dozens of clinical programs simultaneously.
As of its December 2025 balance sheet, Moderna maintains a very strong current ratio of roughly 3.3x. Its debt-to-equity ratio is approximately 0.2x, which suggests a conservative approach to borrowing compared to its total shareholder equity. Free cash flow for the period was negative $2.1 billion. This reflects the intense capital requirements of its broad mRNA platform and global manufacturing network as it scales custom production for new therapies.
Risk profile comparison
Axsome Therapeutics faces significant ongoing financial losses and may eventually require more capital to fund its clinical trials and commercial efforts. The company relies heavily on third-party manufacturers and distribution partners, creating a risk if these partners fail to meet regulatory standards. Competition is also fierce in the CNS market, where Axsome must defend its market share against large pharmaceutical players such as AbbVie Inc. (ABBV +1.75%), Eli Lilly & Co. (LLY +2.70%), and Jazz Pharmaceuticals Inc,. (JAZZ -0.09%).
Moderna faces intense competition in the infectious disease and oncology sectors from established giants like Pfizer Inc. (PFE +1.82%), GSK plc (GSK +0.90%), and Sanofi SA (SNY +1.62%). There is high uncertainty regarding the clinical success and regulatory approval of its broad mRNA pipeline, as many biological pathways involved are not yet fully validated. Additionally, the company deals with complex logistics for its cold-chain products and ongoing risks related to intellectual property litigation and government pricing controls.
Valuation comparison
While both companies are currently reporting net losses, Axsome Therapeutics appears significantly cheaper on both a sales and future earnings basis compared to Moderna.
| Metric | Axsome Therapeutics | Moderna |
|---|---|---|
| Forward P/E | 39.7x | 379.7x |
| P/S ratio | 11.9x | 33.8x |
Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.
The P/S ratio, which measures a company’s market price against its sales over the past twelve months, shows a stark difference in how the market values these two biotechs. The Forward P/E compares the current stock price to future earnings estimates, highlighting the high growth expectations baked into Moderna’s valuation.
Which stock would I buy in 2026?
The COVID-19 vaccine developed by Moderna was a proof of concept of the power of mRNA research to quickly produce new treatments. Unfortunately for Moderna, the decline in people getting the COVID vaccine, along with numerous competitors with their own vaccines, has hammered the company’s revenue in recent years. A more recent RSV vaccine reached the market after competing vaccines, resulting in less-than-robust adoption.
Still, Moderna has some 25 mRNA development candidates across 35 development programs in its portfolio. Seeing those come to market and make a meaningful impact on the business will take some time, however. Next year is likely when one or more of the products will get to market, and it is probably not until 2028 that significant revenue will hit the top line. In fiscal 2026, Moderna is expected to post modest sales growth of about 8% to get close to $2.1 billion in revenue with a much narrower net loss of around $2.8 billion.
Axsome right now is a three-drug business: Auvelity, Sunosi, and Symbravo. But there is a promise of a broadening of the offerings in the future. Axsome has trials ongoing in smoking cessation, ADHD, binge eating disorder, major depressive disorder with symptoms of excessive daytime sleepiness or excessive sleepiness, fibromyalgia, and shift work disorder. It also has programs that are in the works for schizophrenia, epilepsy, and Tourette’s.
Still, the near term is driven by its three offerings. Auvbelity generated $180 million in sales in the second quarter of 2026, with management seeing peak sales of $8 billion. Similarly, Sunosi brought in $36 million in quarterly sales, with management saying its peak could be $300 million to $500 million one day.
Axsome’s long runway for further growth and its much more reasonable ratios compared to Moderna make it the better buy for 2026.
